K. Mamlouk

发表

Continuing Educational Needs of US-Practicing Oncologists Managing Patients with Pancreatic Cancer

B. Mirakhur, Benjamin L. Musher, W. Cerenzia, 2018 .

Real-world dosing patterns of patients (pts) with metastatic pancreatic cancer (mPC) treated with liposomal irinotecan (nal-IRI) in US oncology clinics.

A. Barzi, T. Bekaii-Saab, R. Miksad, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Tazemetostat in relapsed/refractory follicular lymphoma: a propensity score–matched analysis of E7438-G000-101 trial outcomes

B. Cheson, D. Gupta, D. Nellesen, 2022, Oncotarget.

4 Activity of galeterone in castrate-resistant prostate cancer (CRPC) with C-terminal AR loss: Results from ARMOR2

E. Antonarakis, E. Heath, V. Njar, 2014 .

Endoscopic harvest of the medial gastrocnemius muscle flap: a cadaveric study.

M. Revol, J. Servant, R. Vanwijck, 2002, British journal of plastic surgery.

Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer

N. Vogelzang, W. Edenfield, M. Eisenberger, 2015, Clinical Cancer Research.

Treatment With Galeterone in an Elderly Man With Castration-Resistant Prostate Cancer: A Case Report.

M. Taplin, B. Montgomery, R. McKay, 2015, Clinical genitourinary cancer.

Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin.

D. V. Von Hoff, D. Melisi, Li‐Tzong Chen, 2019, European journal of cancer.

Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial.

G. Bodoky, D. Cunningham, Chung-Pin Li, 2018, European journal of cancer.

Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States

A. Barzi, T. Bekaii-Saab, R. Miksad, 2020, Pancreas.

Identifying continuing educational needs among oncologists in managing patients with pancreatic cancer.

B. Mirakhur, Benjamin L. Musher, W. Cerenzia, 2018 .

Clinical activity of avapritinib in ≥ fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST).

Robin L. Jones, O. Mir, W. Tap, 2019, Journal of Clinical Oncology.

Androgen Receptor Modulation Optimized for Response in Splice Variant (ARMOR3-SV): Randomized, open-label, multicenter, controlled study of galeterone versus enzalutamide (enz) in men expressing AR-V7 splice variant (SV), metastatic castrate resistant prostate cancer (mCRPC).

D. Dransfield, K. Ferrante, Jennifer Roberts, 2015 .

Real world outcomes of metastatic pancreatic cancer (mPC) patients (pts) treated with liposomal irinotecan (nal-IRI) in the US.

A. Barzi, T. Bekaii-Saab, R. Miksad, 2018 .